149 related articles for article (PubMed ID: 16603354)
1. 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.
Ni ZJ; Barsanti P; Brammeier N; Diebes A; Poon DJ; Ng S; Pecchi S; Pfister K; Renhowe PA; Ramurthy S; Wagman AS; Bussiere DE; Le V; Zhou Y; Jansen JM; Ma S; Gesner TG
Bioorg Med Chem Lett; 2006 Jun; 16(12):3121-4. PubMed ID: 16603354
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase.
Garbaccio RM; Huang S; Tasber ES; Fraley ME; Yan Y; Munshi S; Ikuta M; Kuo L; Kreatsoulas C; Stirdivant S; Drakas B; Rickert K; Walsh ES; Hamilton KA; Buser CA; Hardwick J; Mao X; Beck SC; Abrams MT; Tao W; Lobell R; Sepp-Lorenzino L; Hartman GD
Bioorg Med Chem Lett; 2007 Nov; 17(22):6280-5. PubMed ID: 17900896
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
6. Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.
Tong Y; Przytulinska M; Tao ZF; Bouska J; Stewart KD; Park C; Li G; Claiborne A; Kovar P; Chen Z; Merta PJ; Bui MH; Olson A; Osterling D; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Oct; 17(20):5665-70. PubMed ID: 17768051
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.
Tong Y; Claiborne A; Stewart KD; Park C; Kovar P; Chen Z; Credo RB; Gu WZ; Gwaltney SL; Judge RA; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem; 2007 Apr; 15(7):2759-67. PubMed ID: 17287122
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
10. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors.
Chen MH; Fitzgerald P; Singh SB; O'Neill EA; Schwartz CD; Thompson CM; O'Keefe SJ; Zaller DM; Doherty JB
Bioorg Med Chem Lett; 2008 Mar; 18(6):2222-6. PubMed ID: 18316187
[TBL] [Abstract][Full Text] [Related]
12. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.
Fraley ME; Steen JT; Brnardic EJ; Arrington KL; Spencer KL; Hanney BA; Kim Y; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2006 Dec; 16(23):6049-53. PubMed ID: 16978863
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.
Song P; Peng P; Han M; Cao X; Ma X; Liu T; Zhou Y; Hu Y
Bioorg Med Chem; 2014 Sep; 22(17):4882-92. PubMed ID: 25042558
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
Liu Z; Yu S; Chen D; Shen G; Wang Y; Hou L; Lin D; Zhang J; Ye F
Drug Des Devel Ther; 2016; 10():1489-500. PubMed ID: 27217720
[TBL] [Abstract][Full Text] [Related]
18. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
[TBL] [Abstract][Full Text] [Related]
19. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.
Dudkin VY; Rickert K; Kreatsoulas C; Wang C; Arrington KL; Fraley ME; Hartman GD; Yan Y; Ikuta M; Stirdivant SM; Drakas RA; Walsh ES; Hamilton K; Buser CA; Lobell RB; Sepp-Lorenzino L
Bioorg Med Chem Lett; 2012 Apr; 22(7):2609-12. PubMed ID: 22374217
[TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
